NuCana (NCNA) Research & Development (2017 - 2025)
NuCana's (NCNA) quarterly Research & Development came in at -$2.3 million in Q4 2025, down 146.79% year-on-year from $4.9 million in Q4 2024, and up 21.21% quarter-over-quarter from -$2.9 million in Q3 2025.
NuCana (NCNA) Research & Development (2017 - 2025) Analysis & Trends
NuCana has disclosed Research & Development across 9 years of filings, most recently posting -$2.3 million for Q4 2025.
- Research & Development for Q4 2025 came in at -$2.3 million, down 146.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.1 million (up 135.29% YoY), and the FY2025 annual result was -$16.8 million, up 27.08% from the prior year.
- Research & Development came in at -$2.3 million for Q4 2025 at NuCana, up from -$2.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $11.9 million in Q2 2021 to a low of -$15.5 million in Q4 2022.
- The 5-year median for Research & Development is -$6.6 million (2023), against an average of -$4.0 million.
- Peak annual rise in Research & Development reached 263.64% in 2021, while the deepest fall reached 257.72% in 2021.
- NuCana's Research & Development stood at -$14.3 million in 2021, then fell by 7.91% to -$15.5 million in 2022, then soared by 44.97% to -$8.5 million in 2023, then jumped by 89.01% to -$935672.8 in 2024, then tumbled by 146.79% to -$2.3 million in 2025.
- The last three Research & Development figures came in at -$2.3 million (Q4 2025), -$2.9 million (Q3 2025), and $9.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -58.00 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.31 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Jun 30, 2025 | 9.48 Mn |
| Mar 31, 2025 | -2.17 Mn |
| Dec 31, 2024 | -935,672.84 |
| Sep 30, 2024 | -4.85 Mn |
| Jun 30, 2024 | 8.54 Mn |
| Mar 31, 2024 | -8.60 Mn |
| Dec 31, 2023 | -8.51 Mn |
| Sep 30, 2023 | -9.42 Mn |
| Jun 30, 2023 | 4.95 Mn |
| Mar 31, 2023 | -8.27 Mn |
| Dec 31, 2022 | -15.47 Mn |
| Sep 30, 2022 | -8.70 Mn |
| Jun 30, 2022 | 8.07 Mn |
| Mar 31, 2022 | -12.67 Mn |
| Dec 31, 2021 | -14.33 Mn |
| Sep 30, 2021 | -12.37 Mn |
| Jun 30, 2021 | 11.91 Mn |
| Mar 31, 2021 | -12.00 Mn |